The analyses of the five previously reported candidate variants in the genes SLC22A2, ERCC1 and ERCC2 did not show a statistically significant association with eGFR decline or CTCAE-AKI in this study’s cohort (Table S7). This evidence concerns the gene ERCC2 and acute kidney injury.